SCHEMBL2980648

SCHEMBL2980648

CNC1CN(C)CC1O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23690734 1.00
SCHEMBL17207705 1.00
SCHEMBL2191971 0.79 NCF1 (0.32)
SCHEMBL2191965 0.79 NCF1 (0.32)
SCHEMBL2191977 0.79 NCF1 (0.32)
SCHEMBL21424003 0.75 ADRB2 (0.30)
SCHEMBL25106072 0.75
SCHEMBL22489212 0.75 ADRB2 (0.30)
SCHEMBL22489609 0.75 ADRB2 (0.30)
SCHEMBL24507486 0.75 FUCA1 (0.39)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230242508-A1 IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF GILEAD SCIENCES, INC. (US) 2023-08-03 US disclosed
US-11524966-B1 Carboxamides as ubiquitin-specific protease inhibitors VALO HEALTH, INC. (US) 2022-12-13 US disclosed
US-20210323975-A1 CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS VALO EARLY DISCOVERY, INC. 2021-10-21 US disclosed
WO-2021147953-A1 PYRIMIDO FIVE-MEMBERED RING DERIVATIVE AND APPLICATION THEREOF 江苏先声药业有限公司 2021-07-29 WO disclosed
US-8754211-B2 Azolotriazinone melanin concentrating hormone receptor-1 antagonists BRISTOL-MYERS SQUIBB COMPANY (US) 2014-06-17 US disclosed
US-20140031337-A1 AZOLOTRIAZINONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS BRISTOL-MYERS SQUIBB COMPANY (US) 2014-01-30 US disclosed
US-8580959-B2 Azolotriazinone melanin concentrating hormone receptor-1 antagonists BRISTOL-MYERS SQUIBB COMPANY (US) 2013-11-12 US disclosed
US-7777032-B2 N-4-[3-Chloro-4-(3-fluoro-benzyloxy)-phenyl]-N6-(3-ethyl-oxazolidin-2-ylidene)-quinazoline-4,6-diamine; use as type I receptor tyrosine kinase inhibitor; hyperproliferation diseases such as cancer; antiinflammatory agents ARRAY BIOPHARMA INC. (US) 2010-08-17 US disclosed
US-20090270621-A1 QUINAZOLINE ANALOGS AS RECEPTOR TYROSINE KINASE INHIBITORS ARRAY BIOPHARMA, INC. (US) 2009-10-29 US disclosed
US-7585975-B2 Quinazoline analogs as receptor tyrosine kinase inhibitors ARRAY BIOPHARMA INC. (US) 2009-09-08 US disclosed
US-7501427-B2 Quinazoline analogs as receptor tyrosine kinase inhibitors ARRAY BIOPHARMA, INC. (US) 2009-03-10 US disclosed
US-20080194558-A1 Quinazoline analogs as receptor Tyrosine Kinase inhibitors ARRAY BIOPHARM, INC. (US) 2008-08-14 US disclosed
US-20050101616-A1 Quinazoline analogs as receptor tyrosine kinase inhibitors ARRAY BIOPHARMA, INC. 2005-05-12 US disclosed